Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 3/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284136 | 0.85 | GPR119 (0.32) | FFAR4SLC8A1ROCK2GPR119 | |
| SCHEMBL6284143 | 0.85 | GPR119 (0.32) | FFAR4SLC8A1ROCK2GPR119 | |
| SCHEMBL6287391 | 0.83 | FFAR4 (0.35) | FFAR4SLC8A1ROCK2GPR119FFAR1 | |
| SCHEMBL6287396 | 0.83 | FFAR4 (0.35) | FFAR4SLC8A1ROCK2GPR119FFAR1 | |
| SCHEMBL6283648 | 0.82 | ADRB3 (0.38) | FFAR4ROCK2GPR119FFAR1 | |
| SCHEMBL6283640 | 0.82 | ADRB3 (0.38) | FFAR4ROCK2GPR119FFAR1 | |
| SCHEMBL6284029 | 0.82 | FFAR4 (0.35) | FFAR4SLC8A1GPR119FFAR1 | |
| SCHEMBL6284018 | 0.82 | FFAR4 (0.35) | FFAR4SLC8A1GPR119FFAR1 | |
| SCHEMBL6280603 | 0.80 | KDM4D (0.34) | FFAR4SLC8A1GPR119FFAR1 | |
| SCHEMBL6280608 | 0.80 | KDM4D (0.34) | FFAR4SLC8A1GPR119FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215594-A1 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | FFAR4 332/4885SLC8A1 1792/4885ROCK2 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.